PMID- 22564585
OWN - NLM
STAT- MEDLINE
DCOM- 20120904
LR  - 20120508
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 44
IP  - 4
DP  - 2012 May
TI  - Role of killer immunoglobulin-like receptor-ligand interactions in human 
      leukocyte antigen-matched sibling hematopoietic stem cell transplantation.
PG  - 919-21
LID - 10.1016/j.transproceed.2012.03.036 [doi]
AB  - INTRODUCTION: Killer immunoglobulin-like receptor (KIR)-ligand mismatches lead to 
      natural killer cell alloreactivity after hematopoietic stem cell transplantation 
      (HSCT). However, their clinical impact on HSCT outcomes is controversial due to 
      complexity of KIR haplotypes, genotypes, and phenotypes as well as their 
      diversity among patient populations. The present study investigated the role of 
      KIR-ligand interactions in human leukocyte antigen (HLA)-matched sibling 
      transplants. METHODS: The recipient cohort, which included patients diagnosed 
      with aplastic anemia, acute leukemia, and myelodysplastic syndrome, received 
      granulocyte-colony stimulating factor (G-CSF)-mobilized peripheral blood stem 
      cells. HLA typing was performed using polymerase chain reaction - sequence 
      specific oligo probes (PCR-SSO). The KIR genotype of the donors and the ligands 
      C1 (Asparagine 80), C2 (Lysine 80), and Bw4 recipient typings were performed 
      using polymerase chain reaction - sequence specific primers (PCR-SSP). We 
      assessed acute and chronic graft-versus-host disease (GVHD), relapse, and overall 
      survival. RESULTS: While 84.5% of donors carried a Bx KIR, 15.5% carried the AA 
      haplotype. The effect of a recipient's lack of ligands among 88.5% of cases was 
      associated with 39% of subjects developing GvHD. Lack of C1 may lead to 
      manifestations of acute GvHD and lack of C2 to manifestation of chronic GvHD. The 
      presence of both C1 and C2 seemed to be protective against both forms of GvHD. 
      The role of two Bw4 alleles, threonine (T) or isoleucine (I) at position 80, was 
      evaluated. 73% of recipients who carried Bw4 80(I) versus 27% with the Bw4 80(T) 
      allele. The presence of Bw4-80(T) allele appeared to reduce the risk of GvHD, 
      indicating its stronger inhibitory effect than its 80(I) counterpart. CONCLUSION: 
      KIR-ligand interactions influenced HSCT outcomes.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Kanga, U
AU  - Kanga U
AD  - Department of Transplant Immunology and Immunogenetics, All India Institute of 
      Medical Sciences, New Delhi, India. umakanga@hotmail.com
FAU - Mourya, M
AU  - Mourya M
FAU - Seth, T
AU  - Seth T
FAU - George, J
AU  - George J
FAU - Sood, P
AU  - Sood P
FAU - Sharma, R
AU  - Sharma R
FAU - Saxena, A
AU  - Saxena A
FAU - Mehra, N K
AU  - Mehra NK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (HLA Antigens)
RN  - 0 (Ligands)
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Anemia, Aplastic/immunology/mortality/*surgery
MH  - Chronic Disease
MH  - Female
MH  - Gene Frequency
MH  - Graft vs Host Disease/genetics/immunology
MH  - HLA Antigens/genetics/*immunology
MH  - Haplotypes
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects/mortality
MH  - *Histocompatibility
MH  - Histocompatibility Testing/methods
MH  - Humans
MH  - India
MH  - Leukemia/immunology/mortality/*surgery
MH  - Ligands
MH  - *Living Donors
MH  - Male
MH  - Myelodysplastic Syndromes/immunology/mortality/*surgery
MH  - Phenotype
MH  - Polymerase Chain Reaction
MH  - Receptors, KIR/genetics/*immunology
MH  - Recurrence
MH  - *Siblings
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2012/05/09 06:00
MHDA- 2012/09/05 06:00
CRDT- 2012/05/09 06:00
PHST- 2012/05/09 06:00 [entrez]
PHST- 2012/05/09 06:00 [pubmed]
PHST- 2012/09/05 06:00 [medline]
AID - S0041-1345(12)00256-4 [pii]
AID - 10.1016/j.transproceed.2012.03.036 [doi]
PST - ppublish
SO  - Transplant Proc. 2012 May;44(4):919-21. doi: 10.1016/j.transproceed.2012.03.036.